Di’ao Group Chengdu Pharmaceutical Co. Ltd. has synthesized glucagon-like peptide-1 receptor (GLP-1R) agonists. They are reported to be useful for the treatment of hypertension, diabetes type 1, cerebral infarction, metabolic dysfunction-associated steatohepatitis (MASH; NASH), metabolic syndrome, obesity, arteriosclerosis and Parkinson’s disease, among others.
Evopoint Biosciences Co. Ltd. has patented 2-acylglycerol O-acyltransferase 2 (MGAT2, MOGAT2) inhibitors. They are described as potentially useful for the treatment of obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, diabetes and arteriosclerosis.
Tetrapharm (Tetra Pharm Technologies ApS) has announced promising preclinical data for TPC-026 for the chronic treatment and long-term management of metabolic disorders, including obesity. The preclinical findings support TPC-026 as a differentiated therapeutic candidate, designed to address underlying disease mechanisms, rather than symptoms alone.
Novo Nordisk A/S has disclosed GLP-1 polypeptide analogues acting as glucagon-like peptide-1 receptor (GLP-1R) agonists. As such, they are reported to be useful for the treatment of obesity and diabetes.
Liver fibrosis in the course of metabolic dysfunction-associated steatohepatitis (MASH) could be significantly reduced using CAR T-cells generated in vivo. Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental cell therapy that eliminates only one type of liver cell, the stellate cells that express fibroblast activation protein alpha (FAP). This strategy not only reduced fibrosis but also reversed liver damage.
Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients.
Corxel Pharmaceuticals Ltd. completed a $287 million series D round to advance its lead compound, an oral small-molecule GLP-1 receptor agonist, CX-11, for obese and overweight patients.
Alveus Therapeutics Inc. has obtained IND clearance from the FDA for ALV-100, for chronic weight management, enabling initiation of a phase Ib study. Dosing has now commenced in the study.
Lexicon Pharmaceuticals Inc. announced that it received no objections from the U.S. FDA to move pilavapadin, its non-opioid candidate for diabetic peripheral neuropathic pain, into phase III study, pushing company shares up near 20% on the day.
RSS
